Brachytherapy
Volume 8, Issue 1 , Pages 4-6 , January 2009

Counterpoint: Cesium-131: Not ready for prime time

  • Wayne M. Butler

      Affiliations

    • Corresponding Author InformationCorresponding author. Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003-6300, USA. Tel.: +1-304-243-3490; fax: +1-304-243-5047.

References 

  1. Hu JC, Wang Q, Pashos CL, et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008;26:2278–2284
  2. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330–337
  3. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  4. Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472–1477
  5. Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  6. Bittner N, Merrick GS, Galbreath RW, et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72:433–440
  7. Blasko JC, Grimm PD, Sylsvester JE, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57:273–278
  8. Kao J, Stone NN, Lavaf A, et al. (125)I monotherapy using D90 implant doses of 180Gy or greater. Int J Radiat Oncol Biol Phys. 2008;70:96–101
  9. Sharkey J, Cantor A, Solc Z, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005;4:34–44
  10. Butler WM, Stewart RR, Merrick GS. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case control study of permanent prostate brachytherapy patients. Med Phys (in press).
  11. Allen ZA, Merrick GS, Butler WM, et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys. 2005;62:981–987
  12. Bittner N, Merrick GS, Wallner KE, et al. The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy. Brachytherapy. 2007;6:258–266
  13. Merrick GS, Butler WM, Wallner KE, et al. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. Brachytherapy. 2003;2:147–157
  14. Merrick GS, Butler WM, Wallner KE, et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys. 2002;54:1055–1062
  15. Merrick GS, Wallner K, Butler WM, et al. Short-term sexual function after prostate brachytherapy. Int J Cancer. 2001;96:313–319
  16. Nath R, Roberts K, Ng M, et al. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys. 1998;25:2293–2307
  17. Aronowitz JN. The “Golden Age” of prostate brachytherapy: a cautionary tale. Brachytherapy. 2008;7:55–59
  18. Murphy MK, Piper RK, Greenwood LR, et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys. 2004;31:1529–1538
  19. Chen Z, Bongiorni P, Nath R. Dose rate constant of a cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry. Med Phys. 2005;32:3279–3285
  20. Rivard MJ. Brachytherapy dosimetry parameters calculated for a 131Cs source. Med Phys. 2007;34:754–762

PII: S1538-4721(08)00657-0

doi: 10.1016/j.brachy.2008.11.003

Brachytherapy
Volume 8, Issue 1 , Pages 4-6 , January 2009